Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel C Jinks

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
BMC Medical Research Methodology|October 14, 2015
Discrimination-based sample size calculations for multivariable prognostic models for time-to-event dataRachel C Jinks, Patrick Royston, Mahesh K B Parmar
Plos One|March 4, 2025
Evaluating sensitivity and specificity of the DPP Vet TB assay in badgers using Bayesian latent class modelsRachel C Jinks, Sandrine Lesellier, Freya Smith, et al.
European Journal of Cancer (Oxford, England : 1990)|January 11, 2011
Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trialsHans Gelderblom, Rachel C Jinks, Matthew Sydes, et al.
European Journal of Cancer (Oxford, England : 1990)|November 1, 2011
Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: a report from the European Osteosarcoma IntergroupAnne McTiernan, Rachel C Jinks, Matthew R Sydes, et al.
The Lancet. Oncology|March 8, 2013
Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09)Ruth E Langley, Fay H Cafferty, Abdulla A Alhasso, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
BMC Medical Research Methodology|October 14, 2015
Discrimination-based sample size calculations for multivariable prognostic models for time-to-event dataRachel C Jinks, Patrick Royston, Mahesh K B Parmar
Plos One|March 4, 2025
Evaluating sensitivity and specificity of the DPP Vet TB assay in badgers using Bayesian latent class modelsRachel C Jinks, Sandrine Lesellier, Freya Smith, et al.
European Journal of Cancer (Oxford, England : 1990)|January 11, 2011
Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trialsHans Gelderblom, Rachel C Jinks, Matthew Sydes, et al.
European Journal of Cancer (Oxford, England : 1990)|November 1, 2011
Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: a report from the European Osteosarcoma IntergroupAnne McTiernan, Rachel C Jinks, Matthew R Sydes, et al.
The Lancet. Oncology|March 8, 2013
Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09)Ruth E Langley, Fay H Cafferty, Abdulla A Alhasso, et al.
Pageof 1